Evoke Pharma Inc (EVOK)

3.40
0.07 2.10
NASDAQ : Health Care
Prev Close 3.33
Open 3.31
Day Low/High 3.30 / 3.42
52 Wk Low/High 1.72 / 11.11
Volume 184.88K
Avg Volume 76.70K
Exchange NASDAQ
Shares Outstanding 15.39M
Market Cap 50.94M
EPS -1.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Evoke Pharma Initiates Comparative Exposure Pharmacokinetic Study For Gimoti™

Evoke Pharma Initiates Comparative Exposure Pharmacokinetic Study For Gimoti™

Expected to be final clinical trial prior to 505(b)(2) NDA submission

Evoke Pharma Enters Agreement With Rho To Submit NDA For Gimoti

Company on track for late 2017/early 2018 submission

Evoke Pharma Presents Gimoti Efficacy And Safety Data From Phase 3 Trial As Late Breaker At Digestive Disease Week 2017

Data Demonstrate Gimoti Significantly Improves Symptoms in Women with Moderate to Severe Diabetic Gastroparesis

FDA Exempts Evoke From Requirement For Human Factor Validation Study

Company reaffirms NDA submission by year end 2017

Evoke Provides Additional Data Demonstrating Statistically Significant Benefit For Gimoti In Moderate To Severe Patients In Phase 3 Diabetic Gastroparesis Trial

Evoke Provides Additional Data Demonstrating Statistically Significant Benefit For Gimoti In Moderate To Severe Patients In Phase 3 Diabetic Gastroparesis Trial

Nausea and abdominal pain symptoms significantly reduced in patients with higher symptom severity

Evoke Receives Positive NDA Submission Guidance From US FDA For Gimoti

Evoke Receives Positive NDA Submission Guidance From US FDA For Gimoti

Healthy volunteer bridging study to oral metoclopramide to be completed and submitted in NDA with existing safety and efficacy data

Evoke Pharma (EVOK) Stock Slides in After-Hours Trade Despite Narrower Q2 Loss

Evoke Pharma (EVOK) Stock Slides in After-Hours Trade Despite Narrower Q2 Loss

Evoke Pharma (EVOK) reported a smaller-than-anticipated loss for the 2016 second quarter after Monday's closing bell.